Characterization of multivalent pneumococcal conjugate vaccines

Area of Science:

• Immunology
• Vaccinology
• Pharmaceutical Sciences

Background:

• Pneumococcal conjugate vaccines are crucial for preventing invasive pneumococcal disease.
• A heptavalent vaccine targeting specific serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) was developed.
• Formulation challenges included low antigen levels and the presence of aluminium phosphate adjuvant.

Purpose of the Study:

• To evaluate the immunogenicity and antigenicity of a novel heptavalent pneumococcal conjugate vaccine.
• To assess the safety and efficacy of the vaccine in a large clinical trial.
• To support the licensure of the heptavalent pneumococcal vaccine.

Main Methods:

• Type-specific analyses using ELISA (immunogenicity) and rate nephelometry (antigenicity) in rabbits.
• Non-serotype specific assays including Anthrone assay (saccharide) and Lowry assay (protein).
• A large, randomized, double-blinded, multiethnic clinical trial in infants.

Main Results:

• Preclinical analyses provided data supporting vaccine use in infants.
• The clinical trial demonstrated that the heptavalent pneumococcal conjugate vaccine is safe and efficacious.
• Successful scale-up of the formulation process to manufacturing level was achieved.

Conclusions:

• The heptavalent pneumococcal conjugate vaccine is safe and effective in infants.
• The comprehensive preclinical and clinical data support vaccine licensure.
• The study highlights successful manufacturing scale-up for the vaccine.